Centanafadine
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Centanafadine
- Molecular weight
- 209.29
- Structure (SMILES)
- c1ccc2cc([C@]34CNC[C@H]3C4)ccc2c1
- centanafadina
- Centanafadina
- centanafadine
- Centanafadine
- centanafadine [INN]
- CENTANAFADINE [USAN]
- Centanafadine [WHO-DD]
- centanafadine inn
- centanafadine usan
- centanafadine who dd
- CENTANAFADINE, (+)-
- dov 216 419
- dov 216 419 free base
- DOV 216,419
- DOV 216,419 free base
- dov 216419
- DOV-216419
- eb 1020
- eb 1020 free base
- EB-1020
- EB-1020 free base
- CAS registry numbers
- 924012-43-1
- ChEMBL ID
- CHEMBL3301621
- InChIKey
- HKHCSWPSUSWGLI-CABCVRRESA-N
- PubChem compound IDs
- 16095349
- FDA ingredient codes (UNII)
- D2A6T4UH9C
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- centanafadine
- Type
- Synthetic organic
- Drug name stem
- -fadine
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- NET
- Gene symbol
- SLC6A2
- Protein identifier
- P23975
- Median affinity
- 8
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- SERT
- Gene symbol
- SLC6A4
- Protein identifier
- P31645
- Median affinity
- 7.05
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- DAT
- Gene symbol
- SLC6A3
- Protein identifier
- Q01959
- Median affinity
- 7.22
- Affinity units
- pIC50
- Mechanism
- Monoamine transporter inhibitor
- Action type
- Inhibitor
- Target
- Monoamine transporter
- Protein identifier
- P23975
- Mechanism
- Monoamine transporter inhibitor
- Action type
- Inhibitor
- Target
- Monoamine transporter
- Protein identifier
- P31645
- Mechanism
- Monoamine transporter inhibitor
- Action type
- Inhibitor
- Target
- Monoamine transporter
- Protein identifier
- Q01959
Open Targets mechanisms
- Mechanism
- Monoamine transporter inhibitor
- Action type
- Inhibitor
- Target
- Monoamine transporter
- Condition
- Attention Deficit Disorder with Hyperactivity
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003888
- Subject identifier
- D001289
- Condition
- Smoking Cessation
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004319
- Subject identifier
- D016540
- Condition
- Feeding and Eating Disorders
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005203
- Subject identifier
- D001068
- Condition
- Depressive Disorder, Major
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002009
- Subject identifier
- D003865
- Condition identifier
- EFO_0003888
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004319
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005203
- Highest recorded phase
- 2
- Condition identifier
- HP_0000739
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002009
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005582
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007743
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0011918
- Highest recorded phase
- 3
- NCT01939353
- NCT02547428
- NCT03605680
- NCT03605836
- NCT03605849
- NCT04081363
- NCT04398225
- NCT04786730
- NCT05428033
- NCT05066724
- NCT05113953
- NCT05536414
- Hydrogen bond acceptors
- 1
- Hydrogen bond donors
- 1
- Polar surface area
- 12.03
- Calculated partition coefficient (ALogP)
- 2.7
- Calculated partition coefficient (XLogP)
- 3
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 1
- Heavy atoms
- 16
- Molecular formula
- C15H15N
- Monoisotopic mass
- 209.120449483
- Natural product
- No
- Recorded assays
- 6
- Active assays
- 2
Active assay types
- Confirmatory
Related records
Trials (21)
- A Long-term Trial of EB-1020 in Adult Patients With ADHD
- A Long-term Trial of EB-1020 in Pediatric Patients With ADHD
- A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users
- A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020
- A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
- A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
- A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
- A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)
- A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder
- A Trial to Assess How Centanafadine Interacts With Stimulants in the Body
- A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder
- A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder
- A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine
- A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD
- A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
- Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment
- Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients
- Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)
- P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
- Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
In development for (5)
- Anxiety Phase 3
- Attention deficit-hyperactivity disorder Phase 3
- Binge eating disorder Phase 2
- Eating disorder Phase 2
- Major depressive disorder Phase 2